Studies in bioequivalence are the commonly accepted method to demonstrate therapeutic equivalence between two medicinal products. Savings in time and cost are substantial when using bioequivalence as an established surrogate marker of therapeutic equivalence. For this reason the design, performance and evaluation of bioequivalence studies have received major attention from academia, the pharmaceutical industry and health authorities.
Bioequivalence Studies in Drug Development focuses on the planning, conducting, analysing and reporting of bioequivalence studies, covering all aspects required by regulatory authorities. This text presents the required statistical methods, and with an outstanding practical emphasis, demonstrates their applications through numerous examples using real data from drug development.
- Includes all the necessary pharmacokinetic background information.
- Presents parametric and nonparametric statistical techniques.
- Describes adequate methods for power and sample size determination.
- Includes appropriate presentation of results from bioequivalence studies.
- Provides a practical overview of the design and analysis of bioequivalence studies.
- Presents the recent developments in methodology, including population and individual bioequivalence.
- Reviews the regulatory guidelines for such studies, and the existing global discrepancies.
- Discusses the designs and analyses of drug-drug and food-drug interaction studies.
Bioequivalence Studies in Drug Development is written in an accessible style that makes it ideal for pharmaceutical scientists, clinical pharmacologists, and medical practitioners, as well as biometricians working in the pharmaceutical industry. It will also be of great value for professionals from regulatory bodies assessing bioequivalence studies.Content:
Chapter 1 Introduction (pages 1โ16):
Chapter 2 Metrics to Characterize Concentration?Time Profiles in Single? and Multiple?Dose Bioequivalence Studies (pages 17โ36):
Chapter 3 Basic Statistical Considerations (pages 37โ68):
Chapter 4 Assessment of Average Bioequivalence in the RT/TR design (pages 69โ104):
Chapter 5 Power and Sample Size Determination for Testing Average Bioequivalence in the RT/TR Design (pages 105โ122):
Chapter 6 Presentation of Bioequivalence Studies (pages 123โ155):
Chapter 7 Designs with more than Two Formulations (pages 157โ173):
Chapter 8 Analysis of Pharmacokinetic Interactions (pages 175โ203):
Chapter 9 Population and Individual Bioequivalence (pages 205โ282):
Chapter 10 Equivalence Assessment for Clinical Endpoints (pages 283โ306):